Atlas Infectious Disease Practice

Welcome to Atlas Infectious Disease Practice, where your health and the well-being of the community are our top priorities. We take pride in our critical role in safeguarding public health by providing a comprehensive range of services focused on the diagnosis, treatment, management, and prevention of infectious diseases. Our dedicated team of physicians and healthcare professionals are committed to delivering expert care and guidance. Explore the services and affiliations that make us a trusted partner in your health journey

Mission Statement

At Atlas Infectious Disease Practice, we are dedicated to providing exceptional and compassionate care for patients in Palm Beach County and the surrounding areas. Our practice specializes in treating a wide range of infectious diseases, including HIV, tuberculosis, hepatitis, sexually transmitted infections, respiratory illnesses, and more.

As the leading infectious disease doctors near you, we utilize cutting-edge diagnostics and innovative treatments to enhance health outcomes and improve the quality of life for our patients. Our holistic approach focuses not only on treating current infections but also on preventing future ones. We are committed to personalized care, providing education and empowering our patients to actively manage their health.

Conveniently located in Palm Beach County, Atlas Infectious Disease Practice is your trusted partner in managing infectious diseases. Whether you’re seeking proactive Prevention or expert care from the best Infectious Disease Doctors near you, our team is here to help.

.

Services

Services Provided

Hospital Consultation

Office Consultation

Immigration Exams

Travel Consultation

Telemedicine

Yellow Fever Vaccine

HIV medicine

Sexually transmitted infection

employee health

IV infusion

Latest news

Stay Informed

Antibodies Remain 6 Months After Chikungunya Vaccine Administered in Youngest Children

Today, Valneva announced results from its phase 2 clinical trial, which demonstrated positive 6-month antibody persistence and safety for its single-shot chikungunya vaccine, VLA1553 (Ixchiq). 1 “The...

First Participant Enrolled in Phase 2 Study for Investigational Antifungal For Cryptococcal Meningitis

Mycovia Pharmaceuticals is evaluating oteseconazole against the standard of care for treating cryptococcal meningitis. Source link...

Ceftolozane/Tazobactam Shows Strong Activity Against ESBL E coli, But Gaps Remain for K pneumoniae

A recent study presented by Taylor Hein, MLS, at the 2025 MAD-ID Meeting explored the in vitro activity of ceftolozane/tazobactam (C/T) against ESBL-producing Escherichia coli, Klebsiella pneumoniae...

Vancomycin Loading Doses Improve Target Timing and Safety in 61,000+ Cases

A large real-world retrospective cohort study presented at MAD-ID 2025 by Tiffany Lee, PharmD, an infectious diseases pharmacist at InsightRX, evaluated the impact of vancomycin loading doses on...

No Significant Difference Between Doxycycline and Minocycline for Bone and Joint Infections

A multi-hospital retrospective cohort study conducted across Indiana University Health (IU Health) hospitals has found no significant differences in treatment outcomes between doxycycline and...

Immunocompromised Patients on OPAT Face Nearly Double the Risk of 30-Day Readmission

A retrospective study presented at MAD-ID 2025 suggests that immunocompromised (IC) patients receiving outpatient parenteral antimicrobial therapy (OPAT) are at significantly greater risk for...

Gyre Therapeutics’ Hydronidone Meets Primary Endpoint in Phase 3 Hepatitis B Trial

Lungen Lu, MD Image Credit: Hepatology Digest on LinkedIn Hydronidone met the primary endpoint in a pivotal phase 3 trial evaluating its efficacy and safety for the treatment of liver fibrosis in...

Long-Acting, Off-Label Alternative for Serious Bacterial Infections

David Goodman-Meza, MD, PhD The long-acting lipoglycopeptides (laLGPs) dalbavancin and oritavancin, currently indicated for skin and skin structure infections, were as effective as daily standard-of...

VOWST Maintains Consistent Safety Profile in rCDI Patients with Comorbidities

At the 2025 MAD-ID meeting, Dianne Nguyen, MD, head of medical affairs for the pharmaceutical division at Nestlé Health Science, presented new data demonstrating the consistent safety profile of...

Reviewing the Efficacy and Safety of Omadacycline in Immunocompromised Patients

In a new study presented at MAD-ID, omadacycline was found to have an 86% clinical success rate across a wide-range of infections and pathogens in an immunocompromised population. “This is an...

Long-Acting HIV Treatment in Low- and Middle-Income Countries

This Viewpoint discusses the need to develop products, such as long-acting antiretrovirals, for...

New Oral Antibiotic for Gonorrhea on the Horizon

A first-in-class oral antibiotic showed promise treating gonorrhea in a randomized clinical trial...

USPSTF Recommendation: Screening for Syphilis Infection During Pregnancy

This 2025 Recommendation Statement from the US Preventive Services Task Force recommends early...

USPSTF Review: Screening for Syphilis Infection During Pregnancy

This systematic review to support a 2025 US Preventive Services Task Force Recommendation Statement...

Patient Information: Screening for Syphilis Infection During Pregnancy

This JAMA Patient Page describes syphilis infection, risks of congenital syphilis during pregnancy...

Maternal Screening for Congenital Syphilis

Often dismissed as a deadly and dreaded disease of the past, syphilis has made a forceful and...

One Million New Pediatric HIV Cases Predicted If PEPFAR Funding Is Cut

For the past 2 decades, the US President’s Emergency Plan for AIDS Relief (PEPFAR) has provided more...

FDA Clears First At-Home Test for Chlamydia, Gonorrhea, and Trichomoniasis

The US Food and Drug Administration (FDA) recently authorized the first at-home test for chlamydia...

Nonrecommended Antivirals Among Medicare Beneficiaries With HIV

This cross-sectional study examines contemporary evidence on the extent to which Medicare...

Syphilis Exposure During Pregnancy and Childhood Hospital Admissions

This cohort study compares rates of all-cause hospitalization in children exposed to syphilis during...

Communicable disease threats report, 31 May – 5 June 2025, week 23

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 31 May – 5...

Communicable disease threats report, 24-30 May 2025, week 22

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 24-30 May 2025...

Communicable disease threats report, 17-23 May 2025, week 21

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 17-23 May 2025...

Accepted insurances

Schedule appointment

We Are Dedicated To Your Health!

Better Care Starts With Us!

Testimonials

What Our Patients Say About Us!